Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
MULTICENTER CLINICAL-TRIAL OF ZINC ACEXAMATE IN THE PREVENTION OF NONSTEROIDAL ANTIINFLAMMATORY DRUG-INDUCED GASTROENTEROPATHY
Autore:
DELASERNA AR; DIAZRUBIO M; RODRIGO M; GUZMAN MA; DESOLA C; RULL S; PASCUAL D; MASIP C; DEFRUTOS VL; HINOJOSA J; PRIMO J; ALMAGRO P; GRACIA A; MIRALLAS JA; MARTINEZ JB; GIJON J; DEAYALA CP; DEPARGA JS; CABEZAS R; ROCA M; VILARDELL F; LOPEZ G; BANARES A; MORILLAS JD; FERNANDEZ P; POSTIGO JL; HERRERO G; GONZALEZ C; BIXQUERT M; CORTS JR; FERRANDO J; VAZQUEZ J; PEREZ A; GASSO C; NAVARRO F; HERRERIAS JM; CASTILLO A; CANGA F; PADRINO JM; MORILLAS L; COLINA F; PAULINO J; RUBIO C; RODRIGUEZ N; DELGADO M; LARREA A; ESCARTIN P; ALBILLOS A; ABREU L; GARRIDO A; ESPINEL J; IBORRA J; BARBADILLO C; ESTEBAN R; GARCIA S; MARTIN L; CALI R; MEDINA F; RIUTORT J; PERICAS M; FONT B; HERRERA A; CALVO J; MEDINA E; CARBONELL J; ROTES D; BOQUET D; CRESPO M; CAMPOS R; VILLA LF; CUENDE E; ALVAREZ M; BENITA V;
Indirizzi:
HOSP SANTA CRUZ & SAN PABLO,DEPT RHEUMATOL,SANT ANTONI MA CLARET 167 E-08025 BARCELONA SPAIN HOSP CLIN SAN CARLOS,DEPT GASTROENTEROL MADRID SPAIN HOSP VIRGEN NIEVES GRANADA SPAIN HOSP SANT JOAN TARRAGONA SPAIN HOSP SAGUNTO VALENCIA SPAIN HOSP LA PAZ MADRID SPAIN HOSP CLIN SAN CARLOS MADRID SPAIN FDN JIMENEZ DIAZ MADRID SPAIN HOSP CLIN UNIV VALENCIA VALENCIA SPAIN COMPLEJO HOSP XERAL CALDE LUGO SPAIN HOSP CLIN UNIV LA MACARENA SEVILLE SPAIN HOSP 12 OCTUBRE MADRID SPAIN HOSP NUESTRA SENORA ALCAROS CIUDAD REAL SPAIN HOSP PUERTA HIERRO MADRID SPAIN HOSP UNIV PUERTA DEL MAR CADIZ SPAIN POLICLIN MIRAMIR PALMA DE MALLORCA SPAIN HOSP GEN UNIV VALENCIA VALENCIA SPAIN HOSP ESPERANZA BARCELONA SPAIN HOSP SEVERO OCHOA MADRID SPAIN HOSP PRINCIPE ASTURIAS MADRID SPAIN
Titolo Testata:
Journal of rheumatology
fascicolo: 5, volume: 21, anno: 1994,
pagine: 927 - 933
SICI:
0315-162X(1994)21:5<927:MCOZAI>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTI-INFLAMMATORY DRUGS; PEPTIC-ULCER; NSAID GASTROPATHY; RHEUMATIC DISEASE; GASTRIC-LESIONS; THERAPY; CIMETIDINE; ASPIRIN; MUCOSA; INJURY;
Keywords:
ZINC ACEXAMATE; NSAID INDUCED GASTROENTEROPATHY; GASTRIC ULCER; RISK FACTORS; GASTROENTEROPATHY PREVENTION; DUODENAL ULCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
58
Recensione:
Indirizzi per estratti:
Citazione:
A.R. Delaserna et al., "MULTICENTER CLINICAL-TRIAL OF ZINC ACEXAMATE IN THE PREVENTION OF NONSTEROIDAL ANTIINFLAMMATORY DRUG-INDUCED GASTROENTEROPATHY", Journal of rheumatology, 21(5), 1994, pp. 927-933

Abstract

Objective. To assess in a multicenter double blind clinical trial thegastroenteroprotective effect of zinc acexamate (ZAC). Methods. 276 patients with rheumatic disease and history of peptic ulcer or intolerance to nonsteroidal antiinflammatory drugs (NSAID), and requiring treatment with these drugs were included. An initial normal endoscopy was needed for inclusion. Patients were treated with one NSAID (diclofenac, piroxicam, naproxen or ketoprofen) and one capsule (300 mg) of either ZAC (141 patients) or placebo (135 patients) at single nocturnal dose. After 28 days, patients underwent a clinical and endoscopic control. Results. 26 patients withdrew from the trial (10 of ZAC and 16 of placebo) and 41 were lost to followup (22 of ZAC and 19 of placebo). Gastroduodenal mucosal damage was graded according to a modified Lanza score. The incidence of gastric ulcer was null with ZAC and 6.0% with placebo (6 cases) (p < 0.05). The incidence of duodenal ulcer was 0.9% with ZAC (1 case) and 6.0% with placebo (6 cases) (p < 0.05). Overall ulcer incidence was 0.9% with ZAC (1 case) and 12% with placebo (12 cases) (p < 0.001). Nine patients of ZAC group (8%) and 25 of placebo (25%) presented some gastric damage (p < 0.001), and 5 (5%) and 19 (19%) respectively presented some duodenal damage (p < 0.005). After treatment, 88% of patients treated with ZAC and 66% with placebo had a completely normal endoscopy (p < 0.0005). No major side effects were reported through the study.Conclusion. ZAC has shown to be effective and welltolerated for the prevention of NSAID induced gastroduodenal damage in patients with rheumatic disease at risk. The incidence of gastric and duodenal ulcers decreased in 92% (13 times the risk), when compared to placebo.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 05:27:26